JAGX
Jaguar Health, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.62
−20.59%Year over year
Reported trailing growth
- Revenue
- +135.5%
- EBITDA
- +5.9%
- EBIT
- +23.6%
- EPS
- +23.6%
- Free cash flow
- +75.5%
- Operating cash flow
- +75.7%
Forward estimates
Based on analyst estimates
- Revenue
- -80.3%
- EBITDA
- +36.9%
- EPS
- +91.2%
Three-year CAGR
- Revenue
- -1.3%
- EBITDA
- -41.1%
- EBIT
- -46.3%
- Net income
- -38.8%
- EPS
- +82.4%
- Free cash flow
- +119.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026